 | | Vol. 6.31 – 26 August, 2022 |
| |
|
|
| The suppressor of cytokine signaling 2 (SOCS2) was screened out by RNA-seq and bioinformatics analyses as a potential prognosis predictor of HCC radiotherapy and then was determined to promote radiosensitivity in HCC both in vivo or in vitro.
[Cell Death & Differentiation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists showed that the expression of the long noncoding RNA HEPFAL was reduced in HCC tissues.
[Cell Death & Disease] |
|
|
|
| Researchers identified AT-rich interacting domain 3A (ARID3A) as one of the most upregulated stemness-related transcription factors in liver cancer by an in vitro functional screen.
[Cell Death & Disease] |
|
|
|
| The authors showed that T317 dose-dependently increased RalA binding protein 1-associated EPS domain containing 2 (REPS2) expression in normal hepatocytes and HCC cells.
[Acta Pharmacologica Sinica] |
|
|
|
| Inhibition of taurocholate uptake and excretion after a 24-hour treatment with prototypical cholestatic drugs showed that differentiated HuH-7 cells were a suitable model to examine cholestatic hepatotoxicity.
[Scientific Reports] |
|
|
|
| Scientists identified that growth differentiation factor-15 was commonly upregulated in lidocaine-treated cancer cell lines.
[Scientific Reports] |
|
|
|
| Studies in liver cell spheroids made from human stellate and hepatocyte cells showed bone morphogenetic protein 4 (BMP4) to be anti-senescent, anti-steatotic, anti-inflammatory, and anti-fibrotic, whereas Gremlin 1 was pro-senescent and antagonistic to BMP4.
[Nature Metabolism] |
|
|
|
| Researchers demonstrated the critical functions of METTL5 in promoting HCC tumorigenesis in vitro and in mouse models.
[Nature Metabolism] |
|
|
|
|
|
| Scientists review the role of intercellular communication in the HCC microecosystem and discuss the advantages of targeted intercellular communication in the clinical diagnosis and treatment of HCC.
[Biochimica Et Biophysica Acta-Molecular Basis of Disease] |
|
|
|
| The authors summarize the progress of immunotherapy for the treatment of HCC including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies.
[Clinical and Experimental Medicine] |
|
|
|
|
| Arbor Biotechnologies announced that it has entered into an agreement with Acuitas Therapeutics. The companies will combine the optimized delivery of Acuitas’ highly validated lipid nanoparticles technology with Arbor’s CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.
[Arbor Biotechnologies] |
|
|
|
|
| November 2 – 4, 2022
Lyon, France |
|
|
|
|
|
| | Newcastle University – Newcastle Upon Tyne, England, United Kingdom |
|
|
|
| | Michigan State University – East Lansing, Michigan, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | University of Kansas Medical Center – Kansas City, Kansas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
